Critical Medicines Act and NICE Technology Priorities

Episode 12 — 27 May 2026 The EU Critical Medicines Act's provisional agreement introduces supply chain resilience metrics into HTA frameworks, while NICE advances systematic technology adoption and new prioritisation criteria. EMA maintains strong approval rates as European HTA bodies expand beyond traditional pharmacoeconomic assessments. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast

Transcript

SPEAKER_01 0:00

Welcome to Access Brief, the daily AI podcast on HEOR, HTA, and market access. I'm Marcus with Sarah. Today, the EU Critical Medicines Act's HTA implications, NICE's new technology adoption framework, and shifting assessment criteria beyond traditional endpoints. Let's get into it.

SPEAKER_00 0:19

The provisional agreement on the Critical Medicines Act from May 12th is getting attention for supply chain politics, but the HTA implications are more fundamental. Reducing collaborative procurement thresholds from nine to five member states and introducing EU preference requirements fundamentally changes how we build cost-effectiveness models.

SPEAKER_01 0:38

Supply chain resilience metrics in HTA frameworks, that's the real shift here. For critical medicines, including antibiotics, insulin, and painkillers, we're moving beyond clinical and economic endpoints to incorporate procurement security. The question is how these new criteria get weighted against traditional QALY calculations.

SPEAKER_00 0:58

But that's exactly where I see problems. Adding supply chain considerations sounds reasonable until you realize it creates preferential pathways for European manufacturers, regardless of cost-effectiveness ratios. We're essentially embedding industrial policy into HTA decisions.

SPEAKER_01 1:12

I don't see it as preferential. It's risk adjustment. If a lower cost option creates supply vulnerability, that's a real cost that traditional models miss. The framework forces us to quantify geopolitical risk, which is overdue.

SPEAKER_00 1:26

Risk adjustment assumes we can reliably model supply chain failures, which we can't. This creates subjective criteria that can justify any outcome. It's industrial policy disguised as evidence-based assessment.

SPEAKER_01 1:38

The NICE guidance on liver preservation machines shows where systematic technology adoption works. Four specialist machines recommended for routine NHS use, published May 20th, directly addressing the postcode lottery for England's 600 people waiting for transplants.

SPEAKER_00 1:54

This consultation is interesting because it's explicitly about geographic equity rather than pure cost effectiveness. NICE is acknowledging that unequal access based on local charitable funding undermines the entire system. Final guidance expected in August.

SPEAKER_01 2:09

What's notable is how NICE frames this as eliminating geographic health inequalities through evidence-based adoption. They're expanding the value framework beyond individual patient outcomes to system-level equity considerations.

SPEAKER_00 2:23

Exactly, and that connects to their new prioritization framework that became operational with the board meeting on May 29th. Systematic topic prioritization aligned with NHS 10-year plan objectives, digital therapeutics for mental health, diagnostic technologies for early cancer detection.

SPEAKER_01 2:39

The prioritization signals where NICE sees high-impact, high-volume opportunities that address workforce constraints. It's strategic resource allocation rather than reactive assessment.

SPEAKER_00 2:50

The EMA's May CHMP meeting shows the regulatory side maintaining momentum. Eight medicine approvals, including Jascade for idiopathic pulmonary fibrosis, and Vejoice for PIC 3. CA-related overgrowth spectrum disorders. Year-to-date, 36 positive opinions versus three negative.

SPEAKER_01 3:08

Those approval rates highlight the growing divergence between regulatory and HTA barriers. EMA maintains robust approval productivity, but each positive opinion hits increasingly complex HTA frameworks across member states.

SPEAKER_00 3:23

And that's where the Critical Medicines Act creates real friction. Strong EMA approval rates combined with new procurement preferences and supply chain criteria means more regulatory approvals facing non-clinical HTA hurdles.

SPEAKER_01 3:36

But it also means HTA bodies are acknowledging that traditional pharmacoeconomic assessments miss critical considerations. Supply chain resilience, geographic equity, workforce impact. These aren't peripheral issues.

SPEAKER_00 3:49

I'll grant that traditional models have gaps, but expanding criteria without clear waiting methodologies creates opportunities for inconsistent decisions. We're adding complexity without necessarily improving outcomes.

SPEAKER_01 4:01

The complexity reflects reality. European HTA bodies are recognizing that value frameworks must account for strategic autonomy, health equity, and system sustainability beyond individual cost-effectiveness ratios.

SPEAKER_00 4:15

Which sounds sophisticated until you're building dossiers that must satisfy traditional endpoints, plus supply chain metrics, plus equity considerations, plus workforce impact. The evidentiary burden is expanding faster than methodological consensus on how to integrate these criteria.

SPEAKER_01 4:31

Fair point on methodology gaps, but the alternative is maintaining frameworks that miss systemic risks and equity failures. The Critical Medicines Act and NICE's prioritization changes represent necessary evolution, even if implementation remains challenging.

SPEAKER_00 4:47

Evolution toward what, though? More comprehensive assessment or more opportunities for subjective decision making? That's the fundamental tension as European HTA expands beyond traditional boundaries.no.